Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06017609 · ClinicalTrials.gov registry record · Phase 2
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
A Phase 2 study of Chronic Heart Failure, sponsored by Akros Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
- 20
- Study locations
NCT06017609 is a Phase 2 study of Chronic Heart Failure that is active but no longer recruiting, run by Akros Pharma. The registered enrollment target is 314 participants, below the 396-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06017609, a Phase 2 study of Chronic Heart Failure, is active but no longer recruiting, sponsored by Akros Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Conditions Studied
Interventions
- DRUG Placebo Capsules
- DRUG JTT-861 Capsules
Study Locations (20)
Florida
- Nature Coast Clinical Research - Crystal River
- Indago Research & Health Center, Inc. - Hialeah
- Med Research of Florida - Miami
- Pharma Medical Innovation, Inc. - Miami Lakes
- Floridian Clinical Research - Miami Lakes
Texas
- NextStage Clinical Research-Beaumont- (01) - Beaumont
- Cypress Heart and Vascular Center - Cypress
- NextStage Clinical Research-Port Arthur-(02) - Port Arthur
- Sherman Clinical Research - Sherman
- Waco Cardiology Associates - NextStage Clinical Research - Waco
Michigan
- Henry Ford Hospital - Detroit
- Profound Research LLC - Farmington Hills
Arizona
- Arensia Exploratory Medicine Inc. - Phoenix
Illinois
- Affinity Health - Park Ridge
Indiana
- ASHA Clinical Research-Munster, LLC - Hammond
Louisiana
- Monroe Research, LLC - West Monroe
Missouri
- NextStage Clinical Research - (Kansas City [01]) - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06017609
The ClinicalTrials.gov registry entry for NCT06017609 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 396-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (21% lower). The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo Capsules is the first listed.
NCT06017609 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, Michigan.
Frequently Asked Questions
What is clinical trial NCT06017609 about?
NCT06017609 is a clinical study titled "Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction". This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
What is the current status of trial NCT06017609?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2023-12-20. Estimated completion is 2026-12.
What conditions does trial NCT06017609 study?
This clinical trial studies the following conditions: Chronic Heart Failure.
What interventions are being tested in trial NCT06017609?
The interventions under investigation include: Placebo Capsules (DRUG), JTT-861 Capsules (DRUG).
Who is sponsoring clinical trial NCT06017609?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06017609 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
COMPLETED · Phase 2
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
RECRUITING · NA
-
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
RECRUITING · NA
-
The HEARTFELT Study
RECRUITING · NA
-
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.